BeiGene(BGNE)
Search documents
BeiGene(BGNE) - 2020 Q2 - Quarterly Report
2020-08-06 20:17
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-Q ___________________________________________________________ (Mark One) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT P ...
BeiGene(BGNE) - 2020 Q1 - Quarterly Report
2020-05-11 20:35
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-Q ___________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37686 _ ...
BeiGene(BGNE) - 2019 Q4 - Annual Report
2020-03-02 22:03
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37686 BEIGENE, LTD. (Exact Name of Registrant as Specified in its Charter) Cayman Islands 98-1209416 (State or oth ...
BeiGene(BGNE) - 2019 Q3 - Quarterly Report
2019-11-12 21:28
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-Q ___________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-376 ...
BeiGene(BGNE) - 2019 Q2 - Quarterly Report
2019-08-08 20:25
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-Q ___________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37686 __ ...
BeiGene(BGNE) - 2019 Q1 - Quarterly Report
2019-05-09 20:32
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Mark One) | --- | --- | --- | |-------|-------------------------------------------------------------------------|-------| | | _______________________________________________________________________ | | | | | | | | FORM 10-Q | | ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...
BeiGene(BGNE) - 2018 Q4 - Annual Report
2019-02-28 21:26
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K (Mark One) T ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001‑37686 BEIGENE, LTD. (Exact Name of Registrant as Specified in its Charter) Cayman Islands (State or Other Jurisdic ...
BeiGene(BGNE) - 2018 Q4 - Earnings Call Transcript
2019-02-28 06:34
BeiGene (NASDAQ:BGNE) Q4 2018 Earnings Conference Call February 27, 2019 6:00 PM ET Company Participants Howard Liang - Chief Financial Officer and Chief Strategy Officer John Oyler - Chairman, Co-Founder and Chief Executive Officer Xiaobin Wu - General Manager of China and President of BeiGene, Ltd. Eric Hedrick - Interim Chief Medical Officer, Immuno-Oncology Conference Call Participants Vikram Purohit - Morgan Stanley & Co. LLC Yaron Werber - Cowen and Company, LLC Ziyi Chen - Goldman Sachs & Co. Katheri ...